@misc{wang_streptamer_versus_2013, 
author={Wang, X.-C.,Pang, H.,Xu, X.,Schmitt, A.,Freund, M.,Schmitt, M.,Chen, B.-A.},
title={Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells},
year={2013},
howpublished = {journal article},
doi = {https://doi.org/10.1016/j.jfma.2012.02.020},
abstract = {Background/Purpose,Cytomegalovirus (CMV) disease constitutes a serious complication after stem cell transplantation and has been treated by adoptive transfer of donor-derived CMV-specific CD8+ T cells. CMV-specific CD8+ T cells were selected by multimers, and the technologies may alter the function of these T cells. Therefore, here we evaluated the impact of multimer reagents on the function of CD8+ T lymphocytes.,Methods,CMV-specific CD8+ T cells were purified from the peripheral blood of donors using tetra- and streptamer technologies. The functional status of purified CMV-specific CD8+ T cells was assessed by multiparametric immunophenotyping and carboxyfluorescein succinimidyl ester proliferation assays as well as by enzyme-linked immunospot assays.,Results,A similar percentage of CMV-specific CD8+ T cells could be purified by both tetra- (90%) and streptamer (92%) technologies. That constitutes a 30- to 50-fold concentration of CMV-specific CD8+CD45RA+CCR7−effector T cells. Selected cells secreted interferon-gamma and granzyme B upon stimulation with CMVpp65 peptide, thus demonstrating their functionality.,Conclusion,Our study demonstrated that both tetra- and streptamer technologies can be used to purify CMV-specific cytotoxic CD8+ T cells for adoptive T-cell transfer. Both multimer technologies did not have any negative influence on the proliferation of selected T cells. Importantly, streptamer technology is available at good manufacturing practice level.},
note = {Online available at: \url{https://doi.org/10.1016/j.jfma.2012.02.020} (DOI). Wang, X.; Pang, H.; Xu, X.; Schmitt, A.; Freund, M.; Schmitt, M.; Chen, B.: Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells. Journal of the Formosan Medical Association. 2013. vol. 112, no. 6, 338-345. DOI: 10.1016/j.jfma.2012.02.020}}